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than in sinusoidal membrane vesicles, suggesting that 
ATP-dependent transport is localized to this domain. 
Using a mixture of canalicular and sinusoidal membrane 
vesicles, ATP-stimulated uptake of radiolabeled LTC,, 
LTD,, LTE, and N-acetyl-LTE, was observed in mem- 
brane vesicles from normal rat liver but not from the 
mutant Wistar rats. Significantly, LTB, uptake was not 
stimulated by ATP, in contrast to the cysteinyl leuko- 
trienes, suggesting that the cysteine moiety is crucial for 
ATP-dependent transport. Although the ATP-dependent 
component of transport was present only in vesicles 
isolated from control rats, a significant uptake of all 
leukotrienes was seen in the absence of ATP in vesicles 
from both normal and mutant animals. The time course 
of LTC, uptake in the absence of ATP showed a transient 
accumulation of fivefold over equilibrium values (over- 
shoot). This transient accumulation was attributed to 
the binding of LTC, to the surface of plasma membrane 
vesicles and not to the transmembrane movement of 
LTC, into vesicles. However, this interpretation is 
tenuous because other criteria of mediated transport 
were not excluded. The preliminary work of Nishida et 
al. (11) suggests that both ATP-dependent and ATP- 
independent mechanisms function to transport certain 
organic anions across the canalicular membrane into 
bile. 
ATP-stimulated cysteinyl leukotriene uptake in mixed 
liver plasma membrane vesicles was specific for ATP 
because ADP, AMP and ATP analogs had no effect; it 
was inhibited by vanadate but not by ouabain, EGTA, 
acivicin or D-penicillamine. Because ATP-dependent 
transport of f3H1LTC, was not inhibited by doxorubicin, 
daunorubicin, verapamil or a monoclonal antibody to 
P-glycoprotein ((22191, this transport pathway is 
probably distinct from the ATP-dependent primary 
active pump for cytotoxic drugs. 
Initial rates of ATP-stimulated uptake of LTC,, LTD, 
and N-acetyl-LTE, were saturable with increasing con- 
centrations, with apparent K ,  values of 0.25,1.5 and 5.2 
FmoVL, respectively. Uptake of "H-labeled cysteinyl 
leukotrienes was mutually inhibited by unlabeled cys- 
teinyl leukotrienes (except for the lack of inhibition of 
[3H]LTC, uptake by LTE,) and unlabeled DNP-SG. 
From these observations the authors concluded that 
cysteinyl leukotrienes and DNP-SG are transported by 
way of a common transport system and that the carrier 
has a high affinity toward LTC, as compared with 
DNP-SG. However, this conclusion is not warranted 
because no evidence was presented that cysteinyl leu- 
kotrienes actually inhibit the transport of DNP-SG 
across liver membranes and, if so, whether it is a 
competitive inhibition. 
Nevertheless, these findings provide the first direct 
evidence that the four major cysteinyl leukotrienes are 
transported across the canalicular membrane by a 
common ATP-dependent mechanism that is distinct 
from P-glycoprotein. Furthermore, because the ATP- 
stimulated transport system was localized to the cana- 
licular membrane, transport of cysteinyl leukotrienes 
across the sinusoidal membrane is presumably mediated 
by a different ATP-independent mechanism. Additional 
studies are needed to define the physiological signif- 
icance of the ATP-independent components of cysteinyl 
leukotriene transport on both the canalicular and 
sinusoidal membranes and the relation between the 
ATP-dependent transport of cysteinyl leukotrienes 
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CYSTIC FIBROSIS -CORRECT CHLORIDE 
CONDUCTANCE CAN CURE CELLS 
Drurnm ML, Pope HA, Cliff WH, Rommens JM,  Marvin 
SA,  Tsui LC, Collins FS, et al. Correction of cystic 
fibrosis defect i n  vitro by retrovirus-mediated gene 
transfer. Cell 1990;62: 122 7- 1233. 
ABSTRACT 
We have used retrovirus-mediated gene transfer to 
demonstrate complementation of the cystic fibrosis 
(CF) defect in vitro. Amphotropic retroviruses were 
used to transduce a functional cystic dbrosis trans- 
membrane conductance regulator (CFTR) cDNA into 
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CFPAC-1, a pancreatic adenocarcinoma cell line de- 
rived from a patient with CF that stably expresses the 
chloride transport abnormalities characteristic of CF. 
CFPAC-1 cells were exposed to control virus (PW) and 
CFTR-expressing virus (PLJ-CFTR); viral-transduced 
clones were isolated and subjected to molecular and 
physiologic analysis. RNA analysis detected a viral- 
derived CFTR transcript in all of the PW-CFTR clones 
that contained unrearranged proviral sequences. 
Agents that increase intracellular CAMP stimulated 
laaI efflux in PW-CFTR clones but not PLJ clones. 
Whole-cell patch-clamp performed on three re- 
sponding clones showed that the anion efflux responses 
were due to CAMP stimulation of C1 conductance. Our 
findings indicate the expression of the normal CFTR 
gene confers --dependent Cl channel regulation 
on CF epithelial cells. 
Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S, 
Jefferson DM, McCann JD, et al. Expression of cystic 
fibrosis transmembrane conductance regulator corrects 
defective chloride channel regulation in cystic fibrosis 
airway epithelial cells. Nature 1990;347:358-363. 
ABSTRACT 
The cystic fibrosis transmembrane conductance reg- 
ulator (CFTR) was expressed in cultured cystic fibrosis 
airway epithelial cells and C1- channel activation 
assessed in single cells using a fluorescence micro- 
scopic assay and the patch-clamp technique. Ex- 
pression of CFTR, but not of a mutant form of CFTR 
(AF508), corrected the C1 channel defect. Correction of 
the phenotypic defect demonstrates a causal rela- 
tionship between mutations in the CFTR gene and 
defective C1 transport which is the hallmark of the 
disease. 
COMMENTS 
Cystic fibrosis (CF), one of the most common and 
often devastating genetic diseases in white populations, 
has long fascinated clinical investigators and physiolo- 
gists, in part because of its effects on a wide variety of 
epithelial tissues, including the airway epithelium, liver, 
pancreas and intestine. Recently, work on CF has shifted 
into a higher gear as the identification of the presumed 
CF gene (1) has allowed investigators to combine 
molecular biology with physiology to better understand 
the underlying pathophysiology of this scientifically 
appealing and clinically destructive disease. The two 
papers reviewed here constitute a landmark step 
forward in CF research because they both provide strong 
evidence that the previously described “CF” gene is the 
one that is defective in CF tissues and, importantly, 
show that the restitution of a normal gene corrects the 
function defects in cultured cell lines from CF airway 
and pancreatic epithelium. The latter finding sets the 
stage for the development of effective gene therapy for 
CF. 
CF is emerging as a disorder in the regulation of ion, 
specifically chloride, transport in a variety of epithelial 
tissues (2, 3). Many of the well-known clinical features 
of CF, such as inspissated and thickened airway mucus, 
plugging of biliary and pancreatic ducts, inspissated 
intestinal meconium and high sweat chloride, may 
reflect defective secretion of chloride, sodium and water 
by airway and gastrointestinal epithelia or defective 
reabsorption of secreted salts in sweat glands. Indeed, 
the reason for the persistence of the CF gene may be a 
heterozygote advantage - heterozygotes may develop 
much less secretory diarrhea during bacterial, viral or 
parasitic gastrointestinal infections, leading to de- 
creased childhood mortality (4-6). The currently ac- 
cepted model for epithelial salt secretion andor reab- 
sorption includes transcellular movement of chloride 
across epithelial cells through specific membrane 
transport proteins on apical and basolateral cell mem- 
branes. In most epithelia studied to date, one of these 
membrane transporters is a chloride channel (or perme- 
ability) located on the apical cell membrane that allows 
rapid movement of negatively charged C1- ions. C1- ions 
accumulate on one side of the epithelial cell layer, and 
cations (Na’) and water follow the chloride ions by 
electrical and osmotic forces to constitute fluid secretion 
(if C1- is transported to the apical or luminal side) or 
fluid absorption (if C1- is transported to the basolateral 
or blood side). Epithelial electrolyte and fluid transport 
is regulated by a variety of agents, including hormones 
and neurotransmitters, and may be strikingly altered by 
drugs or bacterial products. Indeed, for gastroenterolo- 
gists, cholera is an excellent example of unrestrained 
intestinal chloride secretion that is induced by a bac- 
terial toxin. 
In light of this model, many studies of CF tissues 
demonstrate a defect in epithelial chloride transport, 
specifically a defect in chloride channel function. In early 
studies, decreased permeability to chloride was demon- 
strated in CF sweat glands and airway tissue (2). More 
recent studies have directly examined cell membrane 
chloride transport. Chloride secretion in many epithelial 
tissues is stimulated by agents that increase either cyclic 
AMP (CAMP) or intracellular Ca’ or both by way of the 
opening of apical chloride channels and basolateral 
potassium channels. In contrast, chloride secretion by 
CF airway epithelia, intestinal mucosa and pancreatic 
duct cells can be elicited only by Ca+2-these tissues 
display little or no response to CAMP or any of its 
functional analogues (3, 7). The CF defect is not, 
however, in the CAMP pathwayper se because these cells 
generate adequate CAMP if given appropriate stimuli 
and contain active CAMP-dependent protein kinase. 
Furthermore, CF cells do contain functional chloride 
channels. Patch-clamp studies, in which bits of mem- 
brane containing ion channels are removed from cells 
and studied in isolation, show that CF cells have chloride 
channels that can be opened by nonphysiological ma- 
neuvers such as the imposition of a large transmem- 
brane voltage (8,9). Rather, the defect in CF seems to be 
one of regulation. Chloride channels in normal cells are 
opened when exposed to activated protein kinase A, 
presumably through phosphorylation of the channel 
itself or of an associated regulatory protein, whereas the 
chloride channels in CF cells are not opened by protein 
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kinase A. It  is suggested that the chloride channels in CF 
cells, or an associated regulatory protein, may exhibit 
defects in aphosphorylation site. Because it is likely that 
most epithelial tissues are constantly bombarded by a 
variety of regulatory signals, this defect could explain 
the observed abnormal regulation of C1 secretion and 
of fluid secretion that is seen in CF cells and organs. This 
defect in chloride transport can be identified in cultured 
cells by measuring CAMP-stimulated C1- (or 1 - 1  
transport using radioisotopes, C1- sensitive fluorescent 
dyes or patch-clamp electrophysiological methods that 
assess movement of C1 through membrane channels 
( C 1 ~  currents). 
Progress in the genetics of CF has been equally 
impressive. In 1989, a group of collaborators from the 
Hospital for Sick Children in Toronto and the University 
of Michigan localized a putative gene for CF using a 
combination of linkage analysis based on DNA polymor- 
phisms in a group of affected families and a technique 
called chromosome jumping (1. 10, 11). These investi- 
gators used genetic, not functional, criteria to implicate 
the gene they found to be the CF gene. Mutations of this 
gene are found in most CF patients and in carrier 
parents but not in normal subjects. One mutation 
(AF508), in which a phenylalanine residue is omitted, 
apparently accounts for about 70% of white CF patients, 
but a wide variety of other mutations are now being 
discovered. This gene encodes for a large protein of 1,480 
amino acids with a molecular weight of about 170 kD. 
The encoded protein contams two very similar halves 
with areas that are likely to represent membrane- 
spanning domains, ATP-binding sites and phosphory- 
lation sites. The function of this protein is unknown, 
although it resembles the multidrug resistance 
P-glycoprotein, an ATP-dependent drug pump. The CF 
gene product has been termed the CF transmembrane 
conductance regulator (CFTRI because based on the 
physiological data already reviewed it is likely to 
function as a membrane-associated regulatory protein of 
a chloride channel. 
With the identification of a putative CF gene, it 
became possible to address many questions, including 
the following: 
(a) Does the CFTR gene code for the defective protein 
in CF or is it simply a closely linked gene? 
(b) What is the function of the CFTR protein? 
(c) Can CF be treated by gene therapy? 
The two papers reviewed here examine these issues, 
using the skills of ion transport physiologists and 
molecular biologwts. 
The strategy used by both groups was straight- 
forward- to obtain a full-length complementary DNA 
(cDNA) for the CFTR gene, transfect it into defective CF 
cells and look for changes in CAMP-stimulated halide 
transport. An initial stumbling block for both was the 
inability to obtain a full-length cDNA in bacteria 
Apparently the CFTR gene contains a bacterial pro- 
moter that facilitates transcription of a toxic protein in 
bacteria. The group headed by Welsh (the Rich et al. 
article) a t  the Genzyme Corporation solved the problem 
by using a bacterial strain that produced a low number 
of transcripts. They then transfected copies of the 
normal gene into CF airway cells in primary culture 
using a vaccinia virus vector. Because this vector halts 
cell protein synthesis, the airway cells lived only a short 
time after transfection, and all experiments were per- 
formed as short-term assays. The group headed by 
Frizzell and Wilson (the Drumm et al. article) inserted 
several silent mutations into the normal CFTR gene 
that disrupted the bacterial promoter, inserted the 
CFTR cDNA into a retroviral vector and transfected a 
cell line of pancreatic adenocarcinoma cells (CFPANC) 
derived from a patient with CF. The transfected pan- 
creatic cells constitute a stable system that continuously 
expressed the transfected gene. Both groups successfully 
transfected CF cells with the normal CFTR gene and 
demonstrated the presence of the appropriate mes- 
senger RNA, protein or both. Cells transfected with the 
viral vector alone (Drumm et al.) or with the CF AF508 
(defective) CFTR gene (Rich et al.) served as controls. 
Both groups showed convincingly that in cells trans- 
fected with the normal CFTR gene, but not in control 
cells, CAMP-dependent halide transport was restored. 
Drumm et al. measured MP-s t imula ted  1251 efflux in 
10 clones of CF pancreatic cells transfected with the 
normal CFTR gene and 10 clones transfected with the 
viral vector. All nine clones that expressed the complete 
CFTR gene exhibited CAMP-stimulated lZ5I transport in 
contrast to none of the control clones. Interestingly, 
however, these investigators noted a poor correlation 
between the amount of CFTR messenger RNA in 
transfected cells and the extent of CAMP stimulation of 
halide transport. This is consistent with a role for CFTR 
as a regulatory agent, not as the C1- channel per se. 
Further, Drumm et al. performed whole cell patch- 
clamp recordings of transfected cells. Those cells that 
expressed the normal CFTR gene showed CAMP- 
stimulated C1 currents that were not seen in vector- 
transfected control cells. Similarly, Rich et al. used a 
halide-sensitive fluorescent dye, SPQ, and fluorescence 
microscopy to demonstrate CAMP-dependent halide 
transport in CF airway cells transfected with the normal 
but not the defective (CF) CFTR gene. Rich et al. also 
demonstrated CAMP-dependent anion currents in whole 
cell patch-clamp recordings on transfected cells given 
the normal but not the CF CFTR gene. 
Collectively, these studies, which represent a technical 
tour de force, conclusively show that the normal CFTR 
gene corrects functional abnormalities in halide 
transport in CF cells that are related to CAMP- 
dependent regulation of ion transport. These studies 
suggest that CFTR performs a regulatory function, the 
precise nature of which remains unknown. Finally, the 
work clearly shows that the expression of only one copy 
of the normal CFTR gene can correct CF cells, whereas 
expression of many copies of the defective CF gene 
cannot, suggesting that the defective gene, although 
nonfunctional, is not in and of itself toxic to cells. Thus 
gene therapy, if successful in incorporating a normal 
gene into epithelial cells, may cure CF. 
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Where will this work go from here? Clearly, many 
important questions remain to be answered, but the 
tools now seem to be present to proceed at a rapid pace 
to address many issues, including: (a) At a molecular 
level, what is CFTR, how does it interact with chloride 
channels and does it have other functions? The CFTR 
protein is unlike any other known regulatory protein 
and may represent a whole new level of cell regulation. 
(b) Does a defect in CFTR alone completely reproduce 
the clinical picture of CF? A murine model of CF should 
be possible using the analogous mouse gene and homol- 
ogous recombination in embryonic stem cells. ( c )  Can a 
defect in C1- transport cause the abnormalities in mucin 
sulfation or other protein posttranslational modifi- 
cations that are seen in CF patients? (d) Is the CFTR 
gene expressed in those cells and tissues known to be 
affected in CF? (el Can different defects in CFTR 
account for the wide phenotypic range of CF? Work is 
currently underway to try to correlate different CFTR 
mutations to different phenotypic expression of CF (12). 
Finally, how does this work relate to readers of 
HEPATOLOGY? Hepatobiliary disease is common in pa- 
tients with CF, including patchy biliary cirrhosis, inspis- 
sated bile, abnormal bile ductules, extrahepatic biliary 
strictures and gallstones (13, 14). The origin of these 
abnormalities is unclear but could relate to decreased 
hepatic bile flow, decreased bile acid pools, decreased bile 
acid transport and decreased ductular bile formation. It 
is not known currently whether C1- channels are 
important for bile formation by hepatocytes or bile 
ductular cells although C1- channels have been iden- 
tified in the canalicular membrane of rat hepatocytes. 
Interestingly, recent studies have shown that CAMP 
stimulates bile formation (both bile acid-dependent and 
bile acid-independent) and bile acid transport by rat 
hepatocytes (15). Although not conclusive, these 
findings suggest that hepatocytes and/or bile duct cells 
may exhibit a similar CAMP-CFTR-ion transport-fluid 
secretion motif. Clearly, the next few years will be 
interesting and exciting ones for those interested in ion 
transport and disorders thereof. 
REBECCA W. VAN DYKE, M.D. 
Department of Medicine 
University of Michigan 
School of Medicine 
Ann Arbor, Michigan 481 09-0682 
REFERENCES 
1. Riordan JR, Rommens JM, Kerem B-S, Alon N, Rozmahel T, 
Grzelczak Z, Zielenski J ,  et al. Identification of the cystic fibrosis 
gene: cloning and characterization of complementary DNA. 
Science 1989;245:1066-1073. 
2. Quinton PM. Cystic fibrosis: a disease in electrolyte transport. 
3. Welsh MJ. Abnormal regulation of ion channels in cystic fibrosis 
epithelia. FASEB J 1990;4:2718-2725. 
4. Taylor CJ, Baxter PS, Hardcastle J, Hardcastle PT. Failure to 
induce secretion in jejunal biopsies from children with cystic 
fibrosis. Gut 1988;29:957-962. 
5. Berschneider HM, Knowles MR, Azizkhan RG, Boucher RC, Tobey 
FASEB J 1990;4:2709-2717. 
NA, Orlando RC, Powell DW. Altered intestinal chloride transport 
in cystic fibrosis. FASEB J 1988;2:2625-2629. 
6. Romeo G, Devoto M, Galietta LJV. Why is the cystic fibrosis gene 
so frequent? Hum Genet 1989;84:1-5. 
7. Boucher RC, Cheng EHC, Paradiso AM, Stutts MJ, Knowles MR, 
Earp HS. Chloride secretory response of cystic fibrosis human 
airway epithelia. J Clin Invest 1989;84: 1424-1431. 
8. Li M, McCann JD, Liedtke CM, Nairn AC, Greengard P, 
Welsh MJ. Cyclic AMP-dependent protein kinase opens chloride 
channels in normal but not cystic fibrosis airway epithelium. 
Nature 1988;331:358-360. 
9. Schoumacher RA, Schoemaker RL, Halm DR, Tallent EA, Wallace 
RW, Frizzell RA. Phosphorylation fails to activate chloride 
channels from cystic fibrosis airway cells. Nature 1987;330: 
10. Rommens JM, Iannuzzi MC, Kerem B-S, Drumm ML, Melmer G, 
Dean M, Rozmahel R, et al. Identification of the cystic fibrosis 
gene: chromosome walking and jumping. Science 1989;245: 1059- 
1065. 
11. Kerem R-S, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, 
Chakravarti A, Buchwald M, et al. Identification of the cystic 
fibrosis gene: genetic analysis. Science 1989;245: 1073-1080. 
12. Cutting GR, Kasch LM, Rosenstein BJ, Tsui L-C, Kazazian HH J r ,  
Antonarakis SE. Two patients with cystic fibrosis, nonsense 
mutations in each cystic fibrosis gene, and mild pulmonary 
disease. N Engl J Med 1990;323:1685-1689. 
13. Nagel RA, Javaid A, Meire HB, Wise A, Westaby D, Kavani J ,  
Lombard MG, et al. Liver disease and bile duct abnormalities in 
adults with cystic fibrosis. Lancet 1989;2:1422-1425. 
14. Gaskin KJ, Waters DLM, Howman-Giles R, de Silva M, Earl JW, 
Martin HCO, Kan AE, et al. Liver disease and common-bile-duct 
stenosis in cystic fibrosis. N Engl J Med 1988;318:340-346. 
15. Hayakawa T, Bruck R, Ng OC, Boyer JL. DBcAMP stimulates 
vesicle transport and HRP excretion in isolated perfused rat liver. 
Am J Physiol 1990;259:G727-G735. 
752-754. 
p-BLOCKER THERAPY FOR PROPHYLAXIS 
OF INITIAL VARICEAL HEMORRHAGE: HAS 
ITS TIME COME? 
Roberto J .  Groszmann, Jaime Bosch, Norman D. Grace, 
Harold 0. Conn, Guadalupe Garcia-Tsao, Miguel 
Navasa, Jeannie Alberts, et al. Hemodynamic events in 
a prospective randomized trial of propranolol versus 
placebo in the prevention of a first variceal hemorrhage. 
Gastroenterology 1990;99:1401-1407. 
ABSTRACT 
In a double-blind randomized trial, the hemody- 
namic events following the administration of pro- 
pranolol (n = 51) or a placebo (n = 51) were prospec- 
tively studied in cirrhotic patients with esophageal 
varices. The hepatic venous pressure gradient, heart 
rate, and variceal size were determined at the baseline 
and 3,12, and 24 months after the beginning of therapy. 
Baseline values were similar in both groups. At 3 
months, the hepatic venous pressure gradient de- 
creased significantly in propranolol-treated patients 
(from 18.1 * 4.2 to 15.7 & 3.4 mm Hg; P < 0.05) but not 
in patients receiving the placebo (19.6 2 6.8 to 
17.5 2 5.3 mm Hg; NS). At subsequent time intervals 
this gradient decreased significantly from the baseline 
value in both groups. Heart rate decreased signifi- 
cantly in the propranolol-treated group at all times 
(P < 0.001). Variceal hemorrhage occurred in 13 pa- 
tients (11 placebo-, 2 propranolol-treated; P < 0.01), al l  
of whom had a hepatic venous pressure gradient > 12 
mm Hg. In 21 patients (14 propranolol-, 7 placebo- 
